JCO: CheckMate 066 Test. The results of 5 years follow-up of Navuda anti-treatment of advanced melanoma.

The CheckMate 066 trial studied the efficacy and safety of Navudo single-drug therapy as a first-line therapy for the previously untreated BRAF wild type of advanced melanoma.
the results of the five-year follow-up to the trial.
The trial, a multi-center, double-blind Phase III study, recruited 418 patients with non-surgically removable stage III/IV BRAF wild melanoma, randomly assigned to the Navu single resistance group (3 mg/kg.2 weeks) or the Dakabatin group (1000 mg/kg for 3 weeks).
end point is total survival (OS), and secondary endpoints include progress-free survival (PFS), objective mitigation rate (ORR), and safety.
two groups of OS and PFS: Narvon and Dakabazine OS were 37.3 months vs 11.2 months, respectively, PFS was 5.1 months vs 2.2 months after random grouping, followed for at least 60 months (Navu single resistance group and Dakabazine group were followed for 32 months and 10.9 months, respectively).
5-year OS rate was 39% and 17% respectively in the Navu mono-resistance group and the dakabazine group;P and FS rate was 28% and 3%, respectively.
38% of patients who were sent to the dakabazine group and received follow-up treatment (including navuda, n-37).
orR was 42% and 14%, respectively, in the Navuda and Dakabazine groups, and 81% and 39% respectively in patients who survived at 5 years.
37 (88%) of the 42 patients (20%) who received complete remission using Navuda resistance therapy were still alive at the time of the five-year analysis.
of the 75 patients who were still alive and assessable at the time of the five-year analysis using navuda resistance therapy, 83% did not receive follow-up treatment;
results of the security analysis are similar to 3-year reports.
the results of the study's five-year analysis confirmed that narcosin compared to dakabazine can significantly improve all endpoint assessment programs in patients, providing evidence for the long-term use of navudosant anti-monodiopathic maintenance therapy.
patients' survival time is closely related to obtaining a lasting response that can be sustained after treatment has stopped, even without follow-up systematic treatment.
.